A Phase 3 interventional study of Ranibizumab and Dexamethasone implant and sham injections in Visual Impairment, Macular Edema and Central Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.
Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 10th largest by enrollment, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 10th registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 178 across the 26 interventional studies. Of the 22 that completed or were terminated, 19 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
32 studies in Vision Disorders by Novartis: none open now, none under way, none of them phase 3. Of 30 finished, 25 (83%) have results posted.
Among the 32 studies in Vision Disorders by Novartis, this one is the 14th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2011, is one of 17 in phase 3, and was the 6th registered.
Novartis’s Vision Disorders studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ranibizumab in Vision Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Vision Disorders:
This tab as a report to print or save as PDF → With an account.
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: Ranibizumab
Drug: Dexamethasone implant and sham injections
Mean Average BCVA Change From Month 1 Through Month 6 to Baseline
the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6. BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is pproximately 20/20. An increased score indicates improvement in acuity
Time frame: Baseline, month 6
Mean BCVA Change at Month 6
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
Time frame: Baseline, month 6
Number of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the number of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline
Time frame: Baseline, 6 month
Time to Achieve a Significant Improvement ≥ 15 Letters
The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts
Time frame: Baseline, month 6
Change Over Time in BCVA
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
Time frame: Baseline, month 6
Change Over Time of the Central Retinal Thickness (CRT)
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation
Time frame: Baseline, month 6
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function
Time frame: Baseline, month 6
Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires
SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health
Time frame: Baseline, month 6
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires
The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.
Time frame: Baseline, month 6
Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline
The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.
Time frame: Baseline, month 6
| Milestone | Ranibizumab | Dexamethasone |
|---|---|---|
| Started | 124 | 119 |
| Completed | 113 | 72 |
| Not completed | 11 | 47 |
| Withdrew: Adverse event | 2 | 28 |
| Withdrew: Unsatisfactory therapeutic effect | 2 | 13 |
| Withdrew: Consent withdrawn | 4 | 5 |
| Withdrew: Protocol deviation(s) | 0 | 1 |
| Withdrew: Abnormal laboratory value(s) | 1 | 0 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6. BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is pproximately 20/20. An increased score indicates improvement in acuity
| Letters | Ranibizumab | Dexamethasone |
|---|---|---|
| Mean Average BCVA Change From Month 1 Through Month 6 to Baseline | 14.6 ± 11.8 | 4.8 ± 16.2 |
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
| Letters | Ranibizumab | Dexamethasone |
|---|---|---|
| Mean BCVA Change at Month 6 | 14.78 (11.24 to 18.32) | -3.17 (-6.80 to 0.46) |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the number of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline
| Participants | Ranibizumab | Dexamethasone |
|---|---|---|
| Gain≥15 letters | 73 | 22 |
| Loss of ≥15 letters | 1 | 31 |
| Gain ≥10 letters | 89 | 38 |
| Loss of ≥10 letters | 4 | 35 |
| Gain ≥5 letters | 104 | 54 |
| Loss of ≥5 letters | 5 | 40 |
The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts
| Time to event (Days) | Ranibizumab | Dexamethasone |
|---|---|---|
| Time to Achieve a Significant Improvement ≥ 15 Letters | 62 (56 to 91) | 98 (63 to NA) |
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
| letters | Ranibizumab | Dexamethasone |
|---|---|---|
| Month 1 | 9.77 (7.27 to 12.27) | 9.54 (6.98 to 12.10) |
| Month 2 | 12.25 (9.59 to 14.91) | 11.04 (8.31 to 13.76) |
| Month 3 | 14.04 (10.92 to 17.16) | 4.99 (1.79 to 8.18) |
| Month 4 | 12.76 (9.48 to 16.04) | -1.73 (-5.09 to 1.63) |
| Month 5 | 13.57 (10.25 to 16.89) | -2.92 (-6.33 to 0.48) |
| Month 6 | 14.78 (11.24 to 18.32) | -3.17 (-6.80 to 0.46) |
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation
| µm | Ranibizumab | Dexamethasone |
|---|---|---|
| Change Over Time of the Central Retinal Thickness (CRT) | -376.7 ± 274.9 | -168.7 ± 288.3 |
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function
| Score on a scale | Ranibizumab | Dexamethasone |
|---|---|---|
| Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires | 6.0 ± 12.1 | 2.0 ± 10.9 |
SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health
| Units on a scale | Ranibizumab | Dexamethasone |
|---|---|---|
| SF-36 physical component (n=116,113) | -0.7 ± 6.3 | 0.4 ± 6.6 |
| SF-36 mental component (n=116,113) | 2.4 ± 8.7 | 0.4 ± 9.2 |
The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.
| Units on a scale | Ranibizumab | Dexamethasone |
|---|---|---|
| Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires | 0.1 ± 13.2 | 2.0 ± 14.8 |
The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.
| Participants | Ranibizumab | Dexamethasone |
|---|---|---|
| Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline | 94 | 105 |
Non-serious events are listed at a 2.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab | — | 10/124 (8.1%) | 77/124 (62.1%) |
| Dexamethasone | — | 16/119 (13.4%) | 99/119 (83.2%) |
| Event | Ranibizumab | Dexamethasone |
|---|---|---|
| IRIS NEOVASCULARISATION (Study eye)Eye disorders | 0/124 | 4/119 |
| GLAUCOMA (Study eye)Eye disorders | 0/124 | 3/119 |
| HYPHAEMA (Study eye)Eye disorders | 0/124 | 3/119 |
| VISUAL ACUITY REDUCED (Study eye)Eye disorders | 0/124 | 3/119 |
| MACULAR OEDEMA (Study eye)Eye disorders | 1/124 | 2/119 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/124 | 2/119 |
| ANGINA PECTORISCardiac disorders | 0/124 | 1/119 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/124 | 1/119 |
| CARDIAC FAILURECardiac disorders | 0/124 | 1/119 |
| MITRAL VALVE INCOMPETENCECardiac disorders | 0/124 | 1/119 |
| Event | Ranibizumab | Dexamethasone |
|---|---|---|
| INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations | 7/124 | 38/119 |
| MACULAR OEDEMA (Study eye)Eye disorders | 13/124 | 19/119 |
| VISUAL ACUITY REDUCED (Study eye)Eye disorders | 8/124 | 19/119 |
| CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders | 16/124 | 13/119 |
| OCULAR HYPERAEMIA (Study eye)Eye disorders | 14/124 | 15/119 |
| EYE PAIN (Study eye)Eye disorders | 15/124 | 14/119 |
| NASOPHARYNGITISInfections and infestations | 9/124 | 12/119 |
| VITREOUS FLOATERS (Study eye)Eye disorders | 5/124 | 11/119 |
| HEADACHENervous system disorders | 7/124 | 10/119 |
| ABNORMAL SENSATION IN EYE (Study eye)Eye disorders | 6/124 | 8/119 |
| Age, Continuous(Years) | Ranibizumab | Dexamethasone | Total |
|---|---|---|---|
| Mean | 65.3 ± 11.4 | 66.9 ± 12.4 | 66.1 ± 11.9 |
| Sex: Female, Male(Participants) | Ranibizumab | Dexamethasone | Total |
|---|---|---|---|
| Female | 52 | 46 | 98 |
| Male | 72 | 73 | 145 |
The record gives a start of Aug 2011, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab